10.66
+0.24(+2.30%)
Currency In USD
Address
11-12 St. James's Square
London, SW1Y 4LB
United Kingdom of Great Britain and Northern Ireland
Phone
44 2074 003 347
Website
Sector
Healthcare
Industry
Biotechnology
Employees
908
First IPO Date
December 08, 2020
| Name | Title | Pay | Year Born |
| Mr. Matthew Gline | Chief Executive Officer & Director | 738,189 | 1984 |
| Dr. Mayukh Sukhatme M.D. | President, Chief Investment Officer & Director | 574,560 | 1976 |
| Dr. Eric Venker M.D., Pharm.D. | President & Chief Operating Officer | 1.28M | 1987 |
| Mr. Richard Pulik | Chief Financial Officer | 2.29M | 1980 |
| Mr. Drew Kramer | Chief Information Officer | 0 | N/A |
| Mr. Alex Gasner | Executive Vice President of Roivant Health | 0 | N/A |
| Dr. Srini Ramanathan Ph.D. | Chief Development Officer | 0 | N/A |
| Dr. Matt Maisak | Chief Operating Officer of Roivant Platforms | 0 | N/A |
| Mr. Josh Chen J.D. | General Counsel | 0 | N/A |
| Ms. Kelly Graff | Head of People | 0 | N/A |
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.